Table 2.
Clinical studies of statins in endometrial cancer.
| Study Type | Findings in Statin Use Group | Results | References |
|---|---|---|---|
| Meta-analysis | Decrease risks and mortality of endometrial cancer. | Risk: RR = 0.81, 95% CI 0.70 to 0.94; OS: HR = 0.71, 95% CI 0.64 to 0.80. | [45] |
| Meta-analysis | Decrease mortality of endometrial cancer. | Mortality: HR = 0.80, 95% CI, 0.66 to 0.95. | [46] |
| Meta-analysis | No protective effect on endometrial cancer. | Risk: RR = 0.88, 95% CI 0.78 to 1.00; long-term use (>5 years) RR = 0.79, 95% CI 0.58 to 1.08. | [47] |
| Meta-analysis | No protective effect on endometrial cancer. | Risk: RR = 0.94, 95% CI 0.82 to 1.07. | [48] |
| Cohort study | No protective effect on endometrial cancer. | HR = 0.67, 95% CI: 0.39 to 1.17. | [49] |
| Cohort study | No protective effect on survival in endometrial cancer. | Mortality: Type I HR 0.92, 95% CI 0.70 to 1.2; type II HR = 0.92, 95%CI 0.65 to 1.29. | [50] |
| Cohort study | No protective effect on endometrial cancer. | Risk: HR = 0.83, 95% CI 0.64 to 1.08. | [51] |
| Cohort study | No protective effect on endometrial cancer. | Recurrence-free survival (82% vs. 83%); disease-specific survival (86% vs. 84%); and OS (77% vs. 75%). | [52] |
| Cohort study | Decrease mortality of endometrial cancer. | Mortality: HR = 0.41, 95% CI 0.20 to 0.82. | [53] |
| Cohort study | Decrease mortality of endometrial cancer. | Mortality: HR = 0.80, 95% CI, 0.74 to 0.88. | [3] |
| Cohort study | Improve DSS of endometrial cancer, especially concurrent use with aspirin. | DSS: HR 0.63, 95% CI 0.40 to 0.99; concurrent use with aspirin HR 0.25, 95% CI 0.09 to 0.70. | [54] |
| Cohort study | Improve OS and PFS of hyperlipidaemic high-grade endometrial cancer. | Mortality: HR = 0.42, 95% CI, 0.20 to 0.87; PFS: HR = 0.47, 95% CI 0.23 to 0.95. | [55] |
| Cohort study | Decrease mortality of endometrial cancer. | Mortality: continuing user HR = 0.70, 95% CI 0.53 to 0.92; new users HR = 0.43, 95% CI 0.29 to 0.65. | [56] |
| Cohort study | Decrease mortality of type I endometrial cancer and statin new user. | Mortality: type I HR = 0.87, 95% CI 0.76 to 1.00; hydrophilic statins HR = 0.84, 95% CI 0.68 to 1.03; new user HR = 0.75, 95% CI 0.59 to 0.95. | [57] |
| Cohort study | Decrease risks of endometrial cancer. | Risk: HR = 0.74, 95% CI 0.59 to 0.94. | [58] |
CI: confidence interval. RR: relative risk. OR: odds ratio. OS: overall survival. HR: hazard ratio. DSS: disease-specific survival. PFS: progression-free survival.